Patent Theme

Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

16,749 US filings from 5,004 companies since 2023 · 2023: 4,091 · 2024: 5,508 · 2025: 5,104 · 2026 YTD: 2,046

Peptides & Proteins

Top companies

Ranked by filings in this theme since 2023. 2026 is partial.

#	Company	Since 2023	2023	2024	2025	2026 YTD	YoY
1	Regeneron Pharmaceuticals, Inc.	286	57	95	88	46	-7.4%
2	Immatics Biotechnologies GmbH	274	96	120	54	4	-55.0%
3	The Regents of the University of California	216	60	70	57	29	-18.6%
4	Bristol-Myers Squibb Company	209	55	74	55	25	-25.7%
5	Hoffmann-La Roche Inc.	174	33	59	52	30	-11.9%
6	Novartis AG	169	44	51	51	23	0.0%
7	The Board of Trustees of the Leland Stanford Junior University	163	42	53	49	19	-7.5%
8	JANSSEN BIOTECH, INC.	146	34	50	48	14	-4.0%
9	AMGEN INC.	125	25	41	40	19	-2.4%
10	Board of Regents, The University of Texas System	121	23	43	34	21	-20.9%
11	Genentech, Inc.	120	26	44	36	14	-18.2%
12	Chugai Seiyaku Kabushiki Kaisha	118	27	40	30	21	-25.0%
13	Xencor, Inc.	116	29	37	36	14	-2.7%
14	Wyvern Pharmaceuticals Inc.	115	1	3	76	35	+2433.3%
15	Merck Sharp & Dohme LLC	110	25	39	30	16	-23.1%
16	GlaxoSmithKline Biologicals SA	95	50	31	11	3	-64.5%
17	Pfizer Inc.	91	28	26	24	13	-7.7%
18	Cue Biopharma, Inc.	86	24	36	21	5	-41.7%
19	Sanofi	85	20	28	29	8	+3.6%
20	Dana-Farber Cancer Institute, Inc.	80	25	23	22	10	-4.3%
21	Gilead Sciences, Inc.	76	17	24	26	9	+8.3%
22	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	75	16	24	25	10	+4.2%
23	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	74	21	19	27	7	+42.1%
24	Incyte Corporation	73	15	23	29	6	+26.1%
25	Boehringer Ingelheim International GmbH	71	21	27	17	6	-37.0%